1 Unravelling the transcriptome of the human tuberculosis lesion and its clinical

2 implications

Kaori L. Fonseca^{1,2}, Juan José Lozano³, Albert Despuig^{1,2}, Dominic Habgood-Coote⁴, Julia Sidorova³, Lilibeth Arias^{1,2}, Álvaro Del Río-Álvarez^{5,6}, Juan Carrillo-Reixach^{5,6}, 3 4 Aaron Goff⁷, Leticia Muraro Wildner⁷, Shota Gogishvili⁸, Keti Nikolaishvili⁸, Natalia 5 Shubladze⁸, Zaza Avaliani^{8,9}, Pere-Joan Cardona^{1,2,10}, Federico Martinón-Torres^{2,11,12}, 6

- Antonio Salas^{2,12,13}, Alberto Gómez-Carballa^{2,12,13}, Carolina Armengol^{5,6}, Simon J Waddell⁷, Myrsini Kaforou^{4,14}, Anne O'Garra^{15,16}, Sergo Vashakidze^{8,17,&}, Cristina 7
- 8 9 Vilaplana^{1,2,10,18, &,*}
- 10
- 11 1. Experimental Tuberculosis Unit (UTE). Fundació Institut Germans Trias i Pujol (IGTP).
- 12 Edifici Mar. Can Ruti Campus. Crtra. de Can Ruti, Camí de les Escoles, s/n. 08916, Badalona; 13 Catalonia; Spain.
- 14 2. Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES). Av.
- 15 Monforte de Lemos, 3-5. Pabellón 11. Planta 0. 28029, Madrid, Spain.
- 16 3. Bioinformatic Platform, Centro de Investigación Biomédica en Red de Enfermedades Hepática
- 17 y Digestivas (CIBERehd), Hospital Clinic, Barcelona, Spain.
- 18 4. Department of Infectious Diseases, Imperial College London, London, United Kingdom.
- 19 5. Childhood Liver Oncology Group, Germans Trias i Pujol Research Institute (IGTP),
- 20 Translational Program in Cancer Research (CARE), Edifici Muntanya. Can Ruti Campus. Ctra.
- 21 de Can Ruti, camí de les Escoles, s/n, 08916 Badalona, Catalonia, Spain.
- 22 6. Liver and Digestive Diseases Networking Biomedical Research Centre (CIBER), 28029 23 Madrid, Spain.
- 24 7. Global Health and Infection, Brighton and Sussex Medical School, University of Sussex, 25 Falmer, Brighton, BN1 9PX, UK.
- 26 8. National Center for Tuberculosis and Lung Diseases (NCTLD). 50, Maruashvili Str. 0101 27 Tbilisi, Georgia.
- 28 9. European University, Tbilisi, Georgia
- 29 10. Hospital Universitari Germans Trias i Pujol (HUGTIP). Microbiological dept. Crtra. Del 30 Canyet, s/n. 08916. Badalona, Catalonia; Spain.
- 31 11. Genetics, Vaccines and Pediatric Infectious Diseases Research Group (GENVIP), Instituto de
- 32 Investigación Sanitaria de Santiago (IDIS) and Universidad de Santiago de Compostela (USC),
- 33 15706, Galicia, Spain.
- 34 12. Translational Pediatrics and Infectious Diseases, Department of Pediatrics, Hospital Clínico 35 Universitario de Santiago de Compostela (SERGAS), 15706, Galicia, Spain.
- 36 13. Unidade de Xenética, Instituto de Ciencias Forenses (INCIFOR), Facultade de Medicina,
- 37 Universidade de Santiago de Compostela, and GenPoB Research Group, Instituto de
- 38 Investigación Sanitaria (IDIS), Hospital Clínico Universitario de Santiago (SERGAS), 15706, 39 Galicia, Spain.
- 40 14. Centre for Paediatrics and Child Health, Imperial College London, United Kingdom
- 41 15. Immunoregulation and Infection Laboratory, The Francis Crick Institute, London, UK
- 42 16. National Heart and Lung Institute, Imperial College, London, UK.
- 43 17. The University of Georgia, Tbilisi, Georgia.
- 44 18. Direcció Clínica Territorial de Malalties Infeccioses i Salut Internacional. Gerència territorial
- 45 Metropolitana Nord, Institut Català de la Salut. Can Ruti Campus. Crtra. del Canyet, s/n. 08916,
- 46 Badalona; Catalonia; Spain.
- 47
- 48 & Sergo Vashakidze and Cristina Vilaplana should be considered last co-authors
- 49

50 *Corresponding Author:

- 51 Cristina Vilaplana, MD, PhD
- 52 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.
- 53 Principal Investigator

- 54 Tuberculosis Experimental Unit (UTE)
- 55 Fundació Institut Germans Trias i Pujol (IGTP)
- 56 Campus Can Ruti. Crtra. De Can Ruti, Camí de les Escoles, s/n.
- 57 Badalona, Barcelona, 08916
- 58 Catalonia (Spain)
- 59 Telephone: +34 93 033 0527
- 60 cvilaplana@igtp.cat
- 61

62 ABSTRACT

63 The granuloma is a complex structure, contributing to the overall spectrum of tuberculosis (TB). We characterised 44 fresh human pulmonary TB lesion samples from 64 65 13 patients (drug-sensitive and multi-drug resistant TB) undergoing therapeutic surgery using RNA-Sequencing. We confirmed a clear separation between the granuloma and 66 adjacent non-lesional tissue, with the granuloma samples consistently displaying 67 68 increased inflammatory profile despite heterogeneity. Using weighted correlation 69 network analysis, we identified 17 transcriptional modules associated with granulomata 70 and demonstrated a gradient of immune-related transcript abundance according to the 71 granuloma's spatial organization. Furthermore, we associated the modular transcriptional 72 signature of the TB granuloma with clinical surrogates of treatment efficacy and TB 73 severity. We show that in patients with severe disease, the IFN/cytokine signalling and 74 neutrophil degranulation modules were overabundant, while tissue organization and 75 metabolism modules were under-represented. Our findings provide evidence of a 76 relationship between clinical parameters, treatment response and immune signatures at 77 the infection site.

78 Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis 79 (*Mtb*), and a major cause of ill-health and mortality worldwide¹. Globally, TB chemotherapy is successful in 85% of drug- sensitive (DS) TB cases². Nevertheless, there 80 is a fraction of patients who will fail treatment and are therefore prone to disease relapse 81 and death, especially in multi drug-resistant (MDR) TB cases³. The formation of 82 granulomas is a hallmark of TB and is crucial for containing and controlling the spread 83 84 of Mtb within the host⁴. The existing literature has demonstrated a high degree of heterogeneity in TB granulomatous lesions⁵. Animal studies involving macaques have 85 86 provided valuable information on granuloma nature and evolution, showing high diversity even within the same host with different grades of bacteria clearance⁶. 87 Moreover, this diversity is observed over the course of infection⁷. These preclinical 88 89 studies are key to understanding how TB lesions evolve, as human studies cannot provide 90 this information unless using surrogates, such as 18-F-fluorodeoxyglucose positron 91 emission tomography-computed tomography (18F-FDG-PET-CT), as demonstrated by 92 Malherbe et al. when correlating images of TB patients obtained using this method with 93 bacillary load^{8,9}.

94 The development of lung cavitary lesions from a granuloma is crucial in TB pathogenesis and is linked to increased transmission and poor outcomes¹⁰. Human TB 95 96 lesion lung biopsies are limited and scarce¹¹, and host factors that drive cavitary lesion 97 formation or trigger or reflect poor clinical outcomes remain unknown. The resection of 98 human pulmonary lesions during therapeutic surgery or autopsies has revealed insights into TB lesion architecture, and immunopathology at the site of disease, which may 99 100 contribute to the emergence of MDR Mtb populations^{12,13}. Moreover, mycobacterial 101 culture from resected granuloma tissue demonstrated that a subset of patients still 102 harboured live *Mtb* bacilli despite showing preoperative microbiological clearance in sputa in both, DS- and MDR-TB patients^{12,14}. 103

104 Subbian et al demonstrated molecular correlation of immune responses to the heterogeneity of granuloma samples from four MDR-TB patients, diversity that the 105 authors linked to lesion maturation¹⁵. Marakalala et al.¹⁶ suggested that the response to 106 *Mtb* might be shaped by the anatomical localization within the granuloma¹⁶. They 107 108 demonstrated a pro-inflammatory center and an anti-inflammatory surrounding tissue by 109 mass spectrometry and lipid quantification. These authors worked with different types of 110 granulomata from six MDR-TB patients and highlighted the heterogenicity of the 111 lesions¹⁶. Dheda et al. were the first authors to characterize the transcriptional response

at anatomically different locations within the granulomas of 14 MDR-TB patients¹¹. They 112 113 showed the cavity wall as the main source of pro-inflammatory activity compared to the 114 lesion centre. However, none of these human studies included DS-TB patients. Finally, a 115 recent study constructed a spatial cell atlas using 6 patients' samples (two DS-TB and one 116 MDR-TB patient undergoing surgery, and three autopsies) to map granuloma structure 117 and composition and contrast it with the peripheral immune responses¹⁷. 118 To our knowledge, no published TB studies have correlated their results with the 119 clinical characteristics of the patients. Based on the hypothesis that characterising human 120 TB lesions at the transcriptomic level could help us to understand the heterogeneity of 121 granulomas and TB pathogenesis in relation to disease presentation, we determined the 122 modular transcriptome signatures of human TB pulmonary lesions from DS- and MDR-123 TB patients who underwent surgery. We also investigated their link to clinical and 124 microbiological surrogates of TB severity and treatment response (Fig. 1). 125

126

127

129 **RESULTS**

130 The human TB granuloma signature shows a distinct and heterogeneous 131 transcriptional profile as compared with non-lesional lung tissue

132 In our study, outlined in Fig. 1, we collected 48 samples from 14 patients and 133 analysed 44 paired samples from 13 patients (7 DS-TB and 6 MDR-TB) to evaluate the 134 human TB lung granuloma transcriptomic changes by RNA sequencing. We analysed 135 total RNA from three different sections: Central Lesion (C; n=6), Internal Wall (I; n=12) 136 and External Wall (E; n=13) collected from each patient's granuloma biopsy. Fewer C-137 samples could be analysed compared to I and E, due to poorer RNA recovery. 138 Additionally, surrounding non-lesional (NL) tissue from the involved lung was collected 139 as a comparator (n=13) (Fig. 2a). Patients were matched according to their sex and *Mtb* 140 drug-sensitivity classification to avoid potential confounding factors (Supplementary 141 Table 1). Moreover, clinical and demographic data and, resected TB lesion characteristics 142 of each participant were assessed at the time of surgery (Supplementary Tables 1 and 2).

143 We found a total of 4,630 significantly differentially expressed genes (DEGs), 144 using DESeq2 with adjusted $p \le 0.05$ (Extended data Fig. 1a and Supplementary Data Set 145 1). Of these, 2,496 genes were over-expressed in lung granuloma tissues, whereas 2,134 146 were under-expressed, as compared to NL lung tissue (Extended data Fig. 1a). The top 147 40 ranked DEGs clearly separated granuloma samples from NL lung samples (Fig. 2b), 148 showing distinct transcriptional profiles for the two tissues. Among them, genes involved 149 in immune system/cytokine signalling (IRF4, CCL19, LTB, JAK3, INPP5D, FCER2, MMP1) and B cell activation and differentiation (CD22, BLNK, CARD11) were over 150 151 expressed, suggesting an inflammatory signature in the granuloma. Seven granuloma 152 lesion samples clustered with NL tissue samples pointing towards heterogeneity in the 153 granuloma transcriptional profiles (Fig. 2b).

Altogether, our data show a distinct segregation of the granuloma lesion when compared to the NL lung tissue with respect to an inflammatory profile, as previously proposed¹¹. Our findings also indicated a diverse range of molecular diversity within the granuloma samples, prompting our decision to delve deeper into the heterogeneity at a transcriptional level.

- 159
- 160
- 161
- 162

163 Compartments within the granuloma reveal distinct gene expression profiles with

164 an enriched inflammatory response across the lesion

165 To further explore the granuloma heterogeneity and investigate the contribution 166 of each granuloma compartment to the TB lesion architecture, we first performed an 167 enrichment analysis derived from single sample Gene Set Enrichment analysis (ssGSEA) 168 using the top 40 DEGs discriminating the granuloma from the NL lung tissue. The 169 expression of these genes in the different tissue compartments revealed a more 170 pronounced enrichment score of these DEGs in central and internal lesion samples, 171 suggesting that these two compartments might be the main contributors for the overall 172 granuloma transcriptional signature (Fig. 3a).

173 Next, we compared the expression profiles derived from each granuloma 174 compartment with the NL tissue. The list of DEGs (DESeq2 with adjusted $p \leq 0.05$) for 175 the C, I and E vs NL tissue comparisons respectively constituted 3,228 (1,539 genes were 176 over-expressed, whereas 1,689 were under-expressed); 5275 (2,676 over-expressed and 177 2,599 under-expressed); and 1,045 genes (552 over-expressed and 493 under-expressed) 178 (Supplementary Data Set 1 and Extended data Fig. 1b). For central and internal 179 compartments, the hierarchical clustering of the 40 most significantly DEGs showed an 180 evident separation when compared each compartment against the NL lung tissue (Fig. 181 3b). Though less noticeable, the external compartment was still distinguishable from the 182 NL tissue. Therefore, the magnitude of differential expression relative to NL decreased 183 gradually towards the edge of the granuloma structures (Fig. 3b).

184 Among the highly variable genes in central lesion, we found genes involved in the 185 immune system/cytokine signalling (CCL19, CXCL10) to be upregulated in comparison 186 to the NL tissue (Fig. 3b). On the other hand, we found extracellular matrix organization-187 related genes to be downregulated (LRP4, MUC15), while others were upregulated 188 (ADAM12, CTSK). Moreover, collagen-encoding genes (COL1A1, COL3A1, COL11A1) 189 were upregulated in the central compartment, which could reflect collagen turnover or 190 fibrosis; as well as of genes associated to immunoglobulin heavy and light chains 191 (*IGHV4–61*, *IGKV1–39*, *IGKV1D*-39, *IGHV1*-18, *IGHV3*-74, IGLV1-40, 192 IGHV4-34, IGHV1-3, IGLV1-51, IGLV2-18, IGHV6-1, IGHV4-55), related to 193 humoral immunity (Fig. 3b). Furthermore, genes involved in complement fixing (C1OA, 194 *C1QB*, *C1QC*) were significantly upregulated, although not among the top 40 DEGs. For 195 the internal compartment, genes involved in the immune system/cytokine signalling 196 (LTB, FCMR, AIM2, CXCL10, IRF8, IRF4) were upregulated compared to NL (Fig. 3b).

Furthermore, immune system/cytokine signalling genes (*LTB*, *CCL19*, *CXCL9*, *TNFAIP3*, *TNFRSF13C*, *FCMR*, *AIM2*, *CXCL10*) were over-expressed in the external
compartment relative to NL (Fig. 3b), evidencing an inflammatory signature throughout
the granuloma lesion.

201 We then applied weighted gene co-expression analysis (WGCNA) to perform a 202 modular analysis of co-expressed genes in the granuloma and in the three compartments 203 separately, comparing all samples to NL control tissues. We identified 17 modules from 204 co-expression networks related to the human TB whole granuloma (Fig. 3c, 205 Supplementary Data Set 2). The identified granuloma modular signature showed that 206 neutrophil degranulation, cell signalling, humoral immunity, extracellular matrix, 207 interferon/cytokine signalling, and innate/pathogen recognition receptors (PRR) modules 208 were overabundant. These observations were consistent throughout the compartments, 209 except for the neutrophil degranulation and innate/PRR modules, which were apparent in 210 the total granuloma and the internal lesion only, but not in the central or external lesions 211 (Fig. 3c). Conversely, the Epithelial to Mesenchymal Transition (EMT), cholesterol 212 biosynthesis and metabolism modules were found to be under-abundant in the whole 213 granuloma and external and internal, but not in the central compartment. In addition to 214 cholesterol and metabolism, the organelle biogenesis module was underrepresented, 215 across all compartments, suggesting that some pathways present in the healthy lung are 216 diminished in granuloma tissue (Fig. 3c).

In summary, our results showed a significant enrichment of modules related to inflammation, including pathways of innate immunity in the TB granuloma and the internal compartment, and of humoral immunity across all compartments. Meanwhile a decrease in modules related to extracellular matrix organisation and cholesterol biosynthesis and metabolism was observed in granuloma tissues.

222

Patients' clinical status is associated with differential modular transcriptomic profiles in TB lesions

The heterogeneity in the host immune response to infection, considering the involvement and contribution of physically distinct compartments, together with the bacteria and the inflammatory environment, defines granuloma fate and disease manifestation^{16,18}. Hence, we next aimed to associate the modular signature changes in the granulomata (considering the three compartments together) from TB patients with surrogates of treatment response and disease severity. As surrogates of response to 231 treatment we used: achieving stable sputum culture conversion (SCC) before or later than 232 2 months after the start of anti-TB treatment (fast or slow converters); drug sensitivity of 233 the infecting *Mtb* isolate; whether the individual is a TB relapse or new TB case; and the 234 number of pulmonary lesions present (Supplementary Data Set 2). As surrogates of 235 disease severity, we used presence of symptoms assessed by the St. George's Respiratory 236 Ouestionnaire (SGRO) symptoms score, stratifying individuals according to SGRO score 237 > 20 or < 20. We quantitatively tested the association of each clinical parameter with each 238 of the significant module's eigengene (ME) expression patterns (Wilcoxon $p \le 0.05$).

- Regarding the SCC, the modular signature of the granuloma revealed a significant association of DNA binding and interferon/cytokine signalling modules with SCC, with the enrichment of these modules being significantly higher in those individuals converting the sputum culture later (FDR < 0.1; Figs. 4a and b). No significant modular expression was found to be associated with *Mtb* drug sensitivity of the individuals, relapsed or new cases, or number of lesions (data not shown).
- 245 When considering severity of TB disease, we found that DNA binding, neutrophil 246 degranulation, interferon/cytokine signalling, cholesterol biosynthesis and myeloid 247 activation modules were significantly overabundant and associated with higher SGRQ 248 symptoms score (FDR < 0.1; Fig. 4a and c), pointing to higher inflammation status with 249 more severe disease manifestation. In contrast, the EMT module was significantly 250 underabundant in these individuals' granulomas (Fig. 4c).

Our data from the granulomas of this patient cohort suggest that those patients exhibiting slow SCC, which reflects a poorer response to treatment and slower clearance of *Mtb*, were associated with greater lung inflammatory responses, mainly driven through the interferon/cytokine signalling axis. Additionally, the granuloma signature in patients with the most severe TB cases was also associated with an increased inflammatory response.

258 **DISCUSSION**

The immune response to *Mtb* constitutes a complex and dynamic interaction 259 260 between the host immune system, the bacteria and lung microenvironment. Throughout 261 infection, the inflammatory response leads to granuloma formation primarily for bacterial 262 containment, while causing extensive tissue remodelling and destruction, which contributes to the clinical spectrum of TB¹⁹. In our study, we transcriptionally 263 264 characterised the host response in human pulmonary TB lesions from patients undergoing therapeutic surgery. Fresh human TB lesion specimens obtained from these lung 265 266 resections (without formalin fixation or paraffin embedding) were transcriptionally profiled using RNA-Seq. Our study provides various advances over previous 267 approaches^{15,20,21}. Firstly, we have used a more robust data set with increased patient 268 269 numbers, which included 44 TB granuloma samples from 13 DS- and MDR-TB patients 270 from the SH-TBL cohort. Secondly, we confirmed a distinct demarcation between 271 granuloma and adjacent non-lesional tissue from the same patient lung. Thirdly, and to 272 our knowledge for the first time, we have identified a transcriptional modular signature 273 within granulomata and linked our findings to clinical/microbiological parameters used 274 as surrogates of TB severity and response to treatment. In patients with more severe 275 disease, our results showed an increased eigengene expression of pro-inflammatory-276 related modules and a decreased eigengene expression of tissue organization modules. 277 Strikingly, those patients with a delayed response to treatment showed an increased DNA 278 binding and interferon/cytokine modular granuloma response, which has major 279 implications for modifying treatment and subsequent clinical management of disease.

280 Granuloma heterogeneity in TB is a well-accepted concept and has been reported in non-human primate models of infection and human lesions^{16,22}. Besides the 281 282 heterogeneity among samples, we were able to identify a clear pattern across all TB 283 patients compared to their own NL control lung tissue. Among the top 40 DEGs, we found 284 genes predominantly encoding proteins related to the inflammatory processes that 285 orchestrate the antimycobacterial response such as CCL19, LTB, FCMR, MMP1 and *IRF4*^{23–27}. *CCL19* gene expression was found to be increased in mouse lungs post-*Mtb*-286 infection to induce lymphoid structures²³. Regarding human studies, previously published 287 blood microarray-derived signatures found up-regulated levels of LTB^{28} when comparing 288 baseline to end-of-treatment samples from TB patients. Moreover, MMP-1 was found to 289 290 be increased in the respiratory secretions from TB patients and to drive extracellular matrix remodelling in a TB murine model²⁶. Recently, MMP1 was also found to be 291

292 differentially expressed in TB lymph node biopsies compared to control samples in a 293 study by Reichmann et al²⁹. Furthermore, FCMR has been considered a target for host-294 directed therapies²⁵, while the transcription factor *IRF4* was found to be required for the 295 generation of Th1 and Th17 subsets of helper T cells and follicular helper T-like cellular responses²⁷. In samples from our patient cohort, we found those genes to be over-296 297 expressed in the granuloma lesion of patients undergoing surgery for unresolved TB. 298 Additionally, the overexpression of immunoglobulin genes in the granuloma suggests 299 their involvement in complement fixation processes, since C1QA, C1QB and C1QC 300 transcripts were also found to be upregulated in our granuloma samples. Previously published blood signatures found up-regulated levels of $C1QC^{30,31}$, when comparing 301 baseline to end-of-treatment samples. Moreover, the expression of this gene has been 302 proposed as a disease severity biomarker³² and linked to poor treatment response³³. 303 304 Collectively, these findings suggest that information on the host response within the 305 granulomata from lung resections from critically ill patients, may inform the clinical 306 management of disease.

307 We explored the granuloma heterogeneity by analysing DEGs between different 308 compartments and applied WGCNA modular analysis to the whole granuloma and separated compartments. In line with Dheda's and Marakalala's studies^{11,16}, we showed 309 310 that both the centre and internal compartments of the TB granuloma lesion present a more 311 perturbed transcript abundance compared to the external lesion compartment, potentially 312 pointing to the trajectory of the host response to Mtb. Our results confirm the involvement 313 of pro-inflammatory-related genes and modules in the human TB granuloma and 314 compartments. The spatial differences within the granuloma in terms of gene expression 315 are supported by other studies^{11,15}. Dheda et al. described the pathways involved in 316 different parts of cavitary lesions from 14 failed MDR-TB subjects that underwent 317 surgery, pointing to the cavity wall as the main source of pro-inflammatory activity¹¹. In 318 line with our findings, they showed that pro-inflammatory pathways were especially over-319 represented in the cavity wall, including nitric oxide production, reactive oxygen species, 320 IL-1, IL-6, IFN- γ and NF- $\kappa\beta$ transcriptional signatures. Furthermore, Subbian et al. 321 demonstrated using four granuloma samples, the involvement of immune cell signalling 322 and activation, interferon response and tissue remodelling processes in the complex TB granuloma microenvironment¹⁵. The modular granuloma signature that we describe 323 324 herein, provides comparable and additional data, albeit in a larger and independent patient 325 cohort.

326 We identified 17 modules from co-expressed networks and mapped a TB 327 granuloma modular signature, consisting of increased neutrophil degranulation, cell 328 signalling, humoral immunity, extracellular matrix, interferon/cytokine signalling and 329 innate/PRR. In our cohort, patients presented advanced TB disease with cavitary TB. We 330 found the neutrophil module to be increased in whole granuloma but not in the central or 331 external lesions, possibly explained by more necrosis in this region, coupled with 332 relatively low RNA abundance in neutrophils. Moreover, the MMP1 gene was 333 overexpressed in the granuloma as compared to NL tissue, which might suggest the 334 involvement of neutrophils through the activity of matrix metalloproteinases. In humans, 335 neutrophil accumulation in the lungs of active TB patients and has been correlated with increased lung pathology and consequent disease progression^{34,35}. The role of neutrophils 336 337 in TB disease progression and pathology has been well documented in experimental mouse models^{36–39}. Additionally, the extracellular matrix, interferon/cytokine signalling 338 339 and innate/PRR modules have been reported to be upregulated in blood from TB patients^{40,41}, demonstrating that whatever is happening at the site of infection can also be 340 341 translated to the periphery. Interestingly, we found that the humoral module was increased 342 in whole granuloma samples, corroborating with the expression of immunoglobulin 343 heavy and light chains transcripts in both central and internal compartments. Our findings 344 are in keeping with a report from Krause et al., demonstrating the presence of different B 345 cell subsets and high levels of *Mtb*-reactive antibodies in human lung tissue⁴².

346 Conversely, the EMT, cholesterol biosynthesis and metabolism modules were 347 decreased in granuloma relative to NL parenchyma. The EMT is linked to wound healing 348 but also to fibrogenesis and scarring⁴³. The downregulation of this module in granuloma, 349 along with its decreased enrichment in more severe TB cases compared to those with 350 milder symptoms, might suggest a disruption in critical processes needed for tissue repair. 351 We also observed increased cholesterol synthesis in individuals experiencing more severe 352 disease in terms of presenting more pronounced symptomatology. Kim et al. proposed 353 dysregulation of host lipid metabolism caused by *Mtb*, tracing the progression of TB granulomas to caseation, cavitation, and eventual disease transmission²⁰. The authors 354 355 suggested that bacterial components could trigger the host's innate immune system, 356 potentially augmenting the synthesis or storage of host lipids. Consequently, in line with these findings²⁰ the upsurge in cholesterol synthesis which we observe herein might 357 358 mirror the impact of *Mtb* on the host lipid metabolism.

359 Indeed, a major novelty of our work is the use of unbiased modular analysis to 360 link the transcriptional signature generated from TB granuloma lesions with patients' 361 clinical surrogates of TB severity and the time taken to clear Mtb in sputum, and thus 362 response to treatment. Specifically, our results show an important inflammation 363 component in granulomas from patients presenting with greater severity of disease and 364 slower response to treatment. Inflammation has been described as key for tissue damage 365 and linked to a blood transcriptional signature in individuals suffering from active TB disease even months before being diagnosed⁴⁴, and radiographic lung disease 366 extension^{7,36,40}, decreasing upon treatment^{40,45}. Tabone et al. revealed differential 367 responses in the blood transcriptional signature among various clinical TB subgroups 368 369 following treatment, observing a reduction in the inflammation and IFN modules 370 alongside B and T cell modular signatures accompanying successful treatment⁴¹. This 371 observation raises the logical assumption that changes induced by treatment at the blood 372 level might parallel alterations occurring at the infection site. In our study, we found an 373 overabundance of the IFN/cytokine signalling and DNA binding modules associated with 374 severe disease, characterized by worsened symptoms and slower bacterial clearance. Our 375 observations also hint at a potential connection between heightened neutrophil 376 degranulation in severe cases and the damaging mechanisms associated with neutrophil-377 mediated inflammation⁴⁶, suggesting a plausible role for this process in exacerbating the 378 severity of the condition. As our study samples were collected after the end of treatment, 379 all cases examined here could be considered difficult or inadequate responders to 380 treatment. This inadequate response may result in a sustained pro-inflammatory profile at 381 the granuloma site or be the consequence of it, and our findings may thus help in future 382 management of disease treatment. Both our data and data from other sources collectively 383 offer the opportunity to use these transcript patterns to monitor treatment response.

384 Our results suggest that the clinical picture mirrors the inflammation happening 385 at the site of infection and confirms what has been previously seen by others indirectly, 386 both in humans and in experimental animal models. Malherbe et al., showed through 18F-387 FDG-PET-CT lung scans that some patients still have an increased FDG uptake in the 388 lesions when compared to surrounding healthy tissue after six months of treatment⁸, and 389 more recently, the authors have related both a larger burden of disease and a slower rate 390 of reduction in scan metrics with delayed sputum coversion⁴⁷. Our data showed that slow 391 sputum converters present different modular expression profiles in TB granulomas when 392 compared to fast sputum converters. To date, the SCC constitutes the only tool endorsed

by the WHO to monitor treatment response⁴⁸ and can be considered a surrogate of disease 393 394 severity. Therefore, achieving SCC after two months of starting treatment has been associated with TB cavity persistence¹⁴ and poor prognosis^{49,50}. In our cohort, the 395 396 proportion of DS-TB/MDR-TB cases in the fast SCC converters was higher (5/8) than in slow converters (4/6), as previously described⁴⁸. Importantly, from our findings, the 397 398 analysis of granulomatous tissue in resected lung samples from patients suggests that the 399 slower SCC converters exhibit the highest expression of inflammatory genes in the lesion 400 after several months, supporting the potential use of SCC at the two-month mark after 401 treatment initiation as a prognostic indicator. On the other hand, time to sputum clearance 402 could enhance treatment monitoring and refine clinical management and might assist in 403 identifying patients who should be prioritized for further therapeutic interventions. 404 Interesting, measures of microbiological treatment success and clinical severity of disease have also been associated with *Mtb* transcriptional profiles in patient sputa⁵¹, suggesting 405 406 that the lesion immunopathology described here also impact *Mtb* lung phenotypes.

407 Our study has some limitations. These TB individuals presented advanced TB 408 disease with cavitary TB, and underwent lung resection surgery, so the results may not 409 be generalisable to the whole spectrum of TB disease. In countries with a high prevalence 410 of MDR-TB, adjunctive surgical resection is a common therapeutic tool which, despite 411 being a major invasive procedure, reduces the transmission burden of MDR-TB and results in favourable outcomes for the patients⁵². However, this approach is uncommon 412 413 in most countries, thus our results help to understand TB host response but may have a 414 direct impact on TB treatment at short term only in high burden countries where resection 415 is practised. Furthermore, given that individuals with TB may have several lesions at 416 varying stages, which can evolve and recede (as shown in experimental animal 417 studies^{4,7,53,54}), expanding the sample size to include several lesions from the same 418 individuals would be beneficial. However, achieving this is practically unfeasible without 419 conducting a complete pulmonectomy or lung section resection. Consequently, working 420 with samples collected *post-mortem* could offer a viable solution, offering substantial 421 insights and information in this regard, although this is limited by the number of TB 422 patients from whom *post-mortem* samples would be available and the quality of the 423 samples collected.

In conclusion, we have defined a robust signature for human advanced TB granuloma lesions, despite the inter granulomata heterogeneity. Moreover, this is the first study showing different modular transcriptomic signature patterns, integrating and co-

427 analysing our findings with TB patients' clinical/microbiological measurements, 428 including severity and response to treatment. Our study provides a considerable dataset 429 on TB granulomas gene expression which will undoubtedly be of broad utility, interest 430 and significance to the scientific community, contributing to an increase in knowledge on 431 TB immunopathology. A better understanding of disease processes and host protective 432 immune responses may help in the clinical management of TB and development of 433 treatment strategies. Most importantly, our findings provide evidence of the clinical 434 picture with a relationship between clinical parameters, treatment response and immune 435 signatures at the infection site.

437 METHODS

438 Ethics

This study is part of the SH-TBL project (ClinicalTrials.gov Identifier: NCT02715271).
The protocol, research methodology and all associated documents (informed consent
sheet, informed consent form) were reviewed and approved by both ethics' committees
at the National Center of Tuberculosis and Lung Diseases (NCTLD) (IRB00007705
NCTLD Georgia #1, IORG0006411) and the Germans Trias i Pujol University Hospital
(EC: PI-16-171). Written informed consent was obtained from all study participants
before enrolment.

446

447 Study design and patient cohort

448 Study participants constituted the SH-TBL cohort, a cross-sectional study recruiting 40 449 adult patients was conducted in the NCTLD in Tbilisi (Georgia), from May 2016 to May 450 2018, after receiving therapeutic surgery indication for their pulmonary TB. All 451 volunteers received standard anti-TB treatment (ATT) regimen according to Georgia 452 national guidelines and achieved sputum culture conversion. Surgery was required due to 453 persistent radiological signs of cavitary lesions on chest X-Ray and computed 454 tomography scan, according to the Georgian National Guideline "Surgical Treatment of 455 Patients with Pulmonary Tuberculosis" based on official guidelines of surgery 456 recommendations for pulmonary TB. Thoracic surgery decisions were made by the 457 NCTLD Resistant Tuberculosis Treatment Committee, composed of two surgeons and 18 458 pulmonary TB specialists.

459

460 Data and sample collection

461 Anonymised data regarding the socio-epidemiological factors, clinical aspects, and 462 information referring to the current TB episode for the SH-TBL cohort were collected 463 using an electronic case report form. TB individuals were classified taking into 464 consideration clinical surrogates of disease severity. According to their sputum 465 conversion date, individuals were categorized as fast (SCC < 2 months) or slow 466 converters (SCC > 2 months). Drug sensitivity of the *Mtb*-infecting isolate was recorded, 467 classifying TB cases as DS or MDR-TB. Presence of symptoms was assessed with the 468 SGRQ symptom score, and a cut off defined by the median SGRQ symptoms value 469 (SGRQ cut off = 20) was used to stratify the individuals: those with an SGRQ score > 20

470 were considered to have more severe TB disease than those with SGRQ score < 20. 471 Relapsed cases and number of lesions were also considered (Supplementary Data Set 2 472 and supplementary Tables 1 and 2). During surgery, TB granuloma lesions of 3.2 cm in 473 diameter (median; 2.2-5.5 cm) were removed according to surgical criteria. In total, 48 474 SH-TBL biological samples were collected for the study. Biopsies from three different 475 sections of TB lesion were collected, namely Central Lesion (C), Internal Wall (I), 476 External Wall (E). In addition, surrounding non-lesional (NL) lung parenchyma tissue, 477 unaffected, by eye and by palpation, was collected from the same patient (Fig. 2a). Biopsy 478 fragments (~0.5 cm³) of tissue samples from 14 patients were collected for RNA-Seq. 479 Fresh tissue samples were incubated in RNAlater solution (Qiagen) at 4°C overnight, 480 before storage at -80°C. Samples were processed in BioSafety Level 3 (BSL-3) 481 laboratory.

482

483 Total RNA extraction

484 For an optimal RNA recovery, TB lesion biopsy samples were divided into 0.16-0.21g 485 single pieces and placed into new tubes. Samples were reduced to powder by mechanical 486 cryofracturing using a BioPulverizer device (Biospec Products) after being cooled in 487 liquid nitrogen. The powdered tissue was then transferred to 2 mL Lysing Matrix D tubes 488 together with lysis solution for homogenization by FastPrep® instrument (MP 489 Biomedicals). RNA was purified using the mirVana miRNA Isolation Kit (Thermo Fisher 490 Scientific), followed by genomic DNA digestion using the DNA-free DNA Removal Kit 491 (Thermo Fisher Scientific) according to manufacturer's instructions. Quantitative and 492 qualitative RNA integrity number equivalent (RINe) values were obtained by Agilent 493 Bioanalyzer 2100 (Agilent Technologies). In general, a standard RINe score for good 494 quality RNA is set at seven. Considering the source and status of the human TB lesion 495 samples, a minimum RINe cut-off of four was established, accepting that low RNA 496 integrity is a potential source of bias in RNA-Sequencing (RNA-Seq) experiments.

497

498 **RNA-Sequencing library preparation, sequencing, and gene alignment**

Purified RNA was diluted to 25 ng/µl per aliquot and then shipped on dry ice to Macrogen
(Seoul, South Korea), where the RNA-sequencing (RNA-Seq) was performed. Libraries
were constructed using the TruSeq Stranded Total RNA LT Sample Prep Kit (Human
Mouse Rat) (Illumina) following the TruSeq Stranded Total RNA Sample Prep guide
(Part #15031048 Rev. E), including prior removal of ribosomal RNA using the RNA

504 Ribo-Zero rRNA Removal Kit (Human/Mouse/Rat) (Illumina). RNA-Seq was performed 505 on an Illumina platform HiSeq 4000 (Illumina), at 50 million reads per sample, 100bp 506 stranded paired-end reads. Pre-processing of raw data included quality control through 507 FastOC (v.011.7) and MultiOC $(v.1.9)^{55}$. Before further steps in read pre-processing, Illumina adapters were trimmed off with Trimmomatic $(v.0.39)^{56}$. The human genome 508 509 sequence GRCh38.89 and human gene annotations were downloaded from the 510 ENSEMBL web repository. Files from each sample were aligned to the human reference 511 genome using the Spliced Transcripts Alignment to a Reference (STAR) package 512 $(v.2.7.5b)^{57}$, with the built-in gene counts quantification mode for stranded RNA-Seq 513 data. BAM files were generated, and the SAMtools package applied to calculate the percentage of successful read alignment against the reference human genome $(v.1.10)^{57}$ 514

515

516 **RNA-seq data analysis**

517 The overall pipeline for data handling, plotting and statistical analysis was conducted in 518 R (v.3.6.2). After STAR mapping, a gene count data table was obtained including C, I, E, 519 and NL samples. Genes with a lower than 50 counts among all the samples were discarded 520 to avoid confounding the differential gene expression analysis, as they had low expression 521 to be reliably quantified. Paired statistical analyses were done globally and separately for 522 each compartment. The set for the RNA-Seq experiments comprised 44 paired samples 523 from 13 patients. Samples from patient SH-TBL03 weren't taken into consideration for 524 the RNA-Seq analysis as the NL tissue sample control was missing. The differential 525 expression analysis from tissue count tables was conducted using the DESeq2 526 Bioconductor package $(v.1.28.1)^{58}$. Genes were considered as significant DEGs when the Benjamini-Hochberg adjusted p-value was equal to or less than 0.05 ($p \le 0.05$). The R 527 528 package heatmap (v.1.0.12) was used to generate heatmaps and dendrograms for the 529 genes and samples by hierarchical clustering after DESeq2 depth normalization. 530 Heatmaps describe the Euclidean distances between samples.

531

532 Enrichment score for the different tissue compartments

533 The expression across compartments of upregulated selected genes differentiating 534 granuloma from non-lesional tissue was performed using single sample Gene Set 535 Enrichment analysis (ssGSEA). ssGSEA is a variation of the GSEA algorithm that instead 536 of calculating enrichment scores for groups of samples and sets of genes, it provides a 537 score for each sample and gene set pair⁵⁹.

539 Weighted gene co-expression network analysis and functional annotation

540 Weighted gene co-expression network analysis (WGCNA) was performed to identify 541 modules using the R package WGCNA. The TB granuloma modules were constructed 542 using the 10,000 most variable genes across all TB samples collected (log2 RNA-seq 543 expression values). To satisfy the scale-free topology criteria and the recommendations 544 for WGCNA use, we chose an optimal soft-threshold ($\beta = 22.5$) to obtain an adjacency 545 matrix from a signed weighted correlation matrix containing pairwise Pearson 546 correlations, generating the corresponding topological overlap measure (TOM). To detect 547 the modules, we applied a dynamic hybrid tree-cut algorithm to detect the computed 548 modules of co-expressed genes (minimum module size of 20, and deep split = 1). Finally, 549 21 modules were obtained. An additional "grey" module was identified in TB granuloma 550 modules, consisting of genes that were not co-expressed with any other genes. The grey 551 module was discarded from further analysis. Moreover, only modules with more than 40 552 genes were annotated. We computed their intramodular connectivity and selected the top 553 five most interconnected genes⁶⁰. Significantly enriched Gene Ontology and canonical pathways from the MSigDB website⁶¹ were computed using clusterProfiler R package⁶². 554 555 Modules were annotated based on representative biological processes from pathways and 556 processes from all three reference databases. Fold enrichment for the WGCNA modules 557 was calculated using the quantitative set analysis for gene expression with the 558 Bioconductor package QuSAGE⁶³. To identify the modules of genes over- or under-559 abundant in TB granuloma, compared to the respective non-lesional lung tissue using 560 log2 expression values using the three compartments. Only modules with enrichment 561 scores with FDR *p*-value < 0.1 were considered significant.

562

563 Association between modules and clinical characteristics

564 The following parameters were used as surrogates of TB severity: presence of symptoms assessed by the SGRQ symptoms score; achieving the SCC before or later than 2 months 565 566 after the start of anti-TB treatment; DS vs MDR-TB case; being a relapse or new TB case; 567 and number of lesions present. We computed the eigengene for each module, defined as 568 the first principal component of the module representing the overall expression level of 569 the module. The relationship of the transcriptomic modules with clinical surrogates of TB 570 severity (SCC and SGRQ symptoms score) was tested using Wilcoxon-rank sum test. 571 Nominal *p*- values were adjusted using the Benjamini-Hochberg approach⁶⁴.

⁵³⁸

572 ACKNOWLEDGEMENTS

The authors would like to thank the patients who agreed to participate in the study and the staff from the NCTLD who helped with the SH-TBL project. The authors thank the support from Comparative Medicine and Bioimage Centre of Catalonia (CMCiB), namely at BSL 3 facility, Eric Garcia for technical support in acquiring the data. The authors, thank William J. Branchett, from The Francis Crick Institute, London, for his input on the manuscript and providing suggestions/changes for improvement.

579 FUNDING

580 This work was supported by: 1) the Plan Nacional I + D + I co-financed by ISCIII-581 Subdirección General de Evaluación and Fondo-EU de Desarrollo Regional (FEDER) 582 through PI16/01511, PI20/01424, CP13/00174, CPII18/00031 and CB06/06/0031. 2) The 583 European Union's Horizon 2020 research and innovation program under grant agreement 584 No 847762. 3) The Catalan Agency for Management of University and Research Grants 585 (AGAUR) through 2017SGR500, 2021 SGR 00920 and 2017 FI B 00797. 4) The 586 "Spanish Society of Pneumology and Thoracic Surgery" (SEPAR) (16/023). 5) The 587 Wellcome Trust, the Medical Research Foundation grants (206508/Z/17/Z and MRF-160-588 0008-ELP-KAFO-C0801) and the NIHR Imperial College BRC to M.K. 6) Wellcome 589 Trust (204538/Z/16/Z) and National Centre for the Replacement, Refinement and 590 Reduction of Animals in Research (NC3Rs) (NC/R001669/1) grants to S.J.W. 7) Á.D.R.-591 Á and J.C-R were supported by AGAUR grant 2022_FI_B00528 and 2019 FI_B01024, 592 respectively. 8) CA received funding from CIBERehd (CB06/04/0033) and AGAUR 593 (2017-SGR-490 and 2021 SGR-01186) and was supported by Ramón y Cajal grant of the 594 Ministry of Science and Innovation of Spain (RYC-2010-07249). 9) AOG is supported 595 by The Francis Crick Institute which receives its core funding from Cancer Research UK 596 (FC001126), the UK Medical Research Council (FC001126), and the Wellcome Trust 597 (FC001126); before that by the UK Medical Research Council (MRC U117565642).

598 AUTHOR CONTRIBUTIONS

599 Conception: CV and SV. Design of the work: CV and SV, with substantial contributions 600 of MK and AOG. KLF, AD, JJL, JS, LA, DHC, Ad R, JCR, AG, LMW, PJC, SV, SG, 601 KN, NS and ZA worked on the acquisition and analysis of data for the work, and all 602 authors made substantial contributions to its interpretation. RNA-Sequencing library 603 preparation, sequencing, gene alignment and initial bioinformatics analysis was 604 performed by AD and DHC, supervised by MK; and paired statistical analysis, single 605 sample Gene Set Enrichment analysis, WGCNA analysis and the association between 606 modules and clinical characteristics were performed by KLF and JJL, supervised by 607 AOG. KLF and CV drafted the work; and CA, FMT, AS, AGC, SV, SW, MK and AOG 608 reviewed it critically for important intellectual content. All authors revised and gave their 609 final approval of the version to be published and agreed to be accountable for all aspects 610 of the work in ensuring that questions related to the accuracy or integrity of any part of 611 the work are appropriately investigated and resolved.

613 **COMPETING INTERESTS**

The authors declare the following competing interests: C.V salary is covered by ISCIII (CPII18/00031) and Fundacio Institut d'Investigació en Ciencies de la Salut Germans Trias I Pujol (IGTP). C.V is an unpaid board member of the following non-profit organizations: the FUITB foundation and the ACTMON foundation. Neither the ISCIII, the IGTP, the FUITB nor ACTMON have had any role in the conceptualization, design, data collection, analysis, decision to publish, or preparation of the manuscript.

620

621 DATA AVAILABILITY

622 Patient's data were transferred to a data frame (SH-TBL Cohort metadata) and are freely

623 accessible (doi: 10.17632/knhvdbjv3r.1). All metadata and sequencing data from this

624 manuscript have been deposited in the National Center for Biotechnology Information

625 Gene Expression Omnibus (GEO) database and will be released after manuscript

626 acceptance in a peer-reviewed scientific journal.

627	REF	ERENCES
628	1.	World Health Organization (WHO). Global Tuberculosis Report. (2022).
629	2.	World Health Organization (WHO). WHO Report on TB 2020. (2020).
630	3.	World Health Organization. Global Tuberculosis Report. (2021).
631	4.	Gil, O. et al. Granuloma encapsulation is a key factor for containing tuberculosis
632		infection in minipigs. PLoS One 5, e10030 (2010).
633	5.	Lenaerts, A., Barry, C. E. & Dartois, V. Heterogeneity in tuberculosis pathology,
634		microenvironments and therapeutic responses. Immunol Rev 264, 288-307 (2015).
635	6.	Lin, P. L. et al. Sterilization of granulomas is common in active and latent
636		tuberculosis despite within-host variability in bacterial killing. Nat Med 20, 75–79
637		(2014).
638	7.	Gideon, H. P. et al. Multimodal profiling of lung granulomas in macaques reveals
639		cellular correlates of tuberculosis control. Immunity 55, 827-846 (2022).
640	8.	Malherbe, S. T. et al. Persisting PET-CT lesion activity and M. tuberculosis
641		mRNA after pulmonary tuberculosis cure. Nat Med 22, 1094 (2016).
642	9.	Penn-Nicholson, A. et al. RISK6, a 6-gene transcriptomic signature of TB disease
643		risk, diagnosis and treatment response. Sci Rep 10, 8629 (2020).
644	10.	Urbanowski, M. E., Ordonez, A. A., Ruiz-Bedoya, C. A., Jain, S. K. & Bishai, W.
645		R. Cavitary tuberculosis: the gateway of disease transmission. Lancet Infect Dis
646		20 , e117–e128 (2020).
647	11.	Dheda, K. et al. Spatial network mapping of pulmonary multidrug-resistant
648		tuberculosis cavities using RNA sequencing. Am J Respir Crit Care Med 200, 370-
649		380 (2019).
650	12.	Kempker, R. R. et al. Additional drug resistance in Mycobacterium tuberculosis
651		isolates from resected cavities among patients with multidrug-resistant or
652		extensively drug-resistant pulmonary tuberculosis. Clinical Infectious Diseases 54,
653		51–54 (2012).
654	13.	Dartois, V. & E. Barry, C. Clinical pharmacology and lesion penetrating properties
655		of second- and third-line antituberculous agents used in the management of
656		multidrug-resistant (MDR) and extensively-drug resistant (XDR) tuberculosis.
657		Curr Clin Pharmacol 5, 96–114 (2010).
658	14.	Vashakidze, S. et al. Retrospective study of clinical and lesion characteristics of
659		patients undergoing surgical treatment for Pulmonary Tuberculosis in Georgia. Int
660		J Infect Dis 56, 200–207 (2017).

- 15. Subbian, S. *et al.* Lesion-specific immune response in granulomas of patients with
 pulmonary tuberculosis: A pilot study. *PLoS One* 10, 1–21 (2015).
- Marakalala, M. J. *et al.* Inflammatory signaling in human tuberculosis granulomas
 is spatially organized. *Nat Med* 22, 531–538 (2016).
- McCaffrey, E. F. *et al.* The immunoregulatory landscape of human tuberculosis
 granulomas. *Nature Immunology* 23, 318–329 (2022).
- 18. Lin, P. L. & Flynn, J. L. The End of the Binary Era: Revisiting the Spectrum of
 Tuberculosis. *The Journal of Immunology* 201, 2541–2548 (2018).
- McCaffrey, E. F. *et al.* The immunoregulatory landscape of human tuberculosis
 granulomas. *Nat Immunol* 23, 318–329 (2022).
- Kim, M. J. *et al.* Caseation of human tuberculosis granulomas correlates with
 elevated host lipid metabolism. *EMBO Mol Med* 2, 258–274 (2010).
- 673 21. McCaffrey, E. F. *et al.* The immunoregulatory landscape of human tuberculosis
 674 granulomas. *Nature Immunology* 23, 318–329 (2022).
- 675 22. Cadena, A. M., Fortune, S. M. & Flynn, J. L. Heterogeneity in tuberculosis. *Nature*676 *Reviews Immunology* 17, 691–702 (2017).
- Kahnert, A. *et al.* Mycobacterium tuberculosis triggers formation of lymphoid
 structure in murine lungs. *Journal of Infectious Diseases* 195, 46–54 (2007).
- Agyekum, S. *et al.* Expression of lymphotoxin-beta (LT-beta) in chronic
 inflammatory conditions. *J Pathol* 199, 115–121 (2003).
- 681 25. Wang, H., Coligan, J. E. & Morse, H. C. Emerging Functions of Natural IgM and
 682 Its Fc Receptor FCMR in Immune Homeostasis. *Front Immunol* 7, (2016).
- Elkington, P. *et al.* MMP-1 drives immunopathology in human tuberculosis and
 transgenic mice. *J Clin Invest* 121, 1827 (2011).
- 685 27. Swanson, R. V. *et al.* Antigen-specific B cells direct T follicular-like helper cells
 686 into lymphoid follicles to mediate Mycobacterium tuberculosis control. *Nature*687 *Immunology* 24, 855–868 (2023).
- 688 28. Cliff, J. M. *et al.* Distinct phases of blood gene expression pattern through
 689 tuberculosis treatment reflect modulation of the humoral immune response. *J Infect*690 *Dis* 207, 18–29 (2013).
- Reichmann, M. T. *et al.* Integrated transcriptomic analysis of human tuberculosis
 granulomas and a biomimetic model identifies therapeutic targets. *Journal of Clinical Investigation* 131, (2021).

- Bloom, C. I. *et al.* Detectable Changes in The Blood Transcriptome Are Present
 after Two Weeks of Antituberculosis Therapy. *PLoS One* 7, e46191 (2012).
- 696 31. Ottenhoff, T. H. M., Dass, R. H., Yang, N., Zhang, M. M. & Wong, H. E. E.
- 697 Genome-Wide Expression Profiling Identifies Type 1 Interferon Response
 698 Pathways in Active Tuberculosis. *PLoS One* 7, 45839 (2012).
- 699 32. Cai, Y. *et al.* Increased complement C1q level marks active disease in human
 700 tuberculosis. *PLoS One* 9, (2014).
- 701 33. Cliff, J. M. *et al.* Distinct phases of blood gene expression pattern through
 702 tuberculosis treatment reflect modulation of the humoral immune response. *J Infect*703 *Dis* 207, 18–29 (2013).
- Eum, S.-Y. *et al.* Neutrophils Are the Predominant Infected Phagocytic Cells in
 the Airways of Patients With Active Pulmonary TB. *Chest* (2010).
- Gopal, R. *et al.* S100A8/A9 proteins mediate neutrophilic inflammation and lung
 pathology during tuberculosis. *Am J Respir Crit Care Med* 188, 1137–1146 (2013).
- Moreira-Teixeira, L. *et al.* Mouse transcriptome reveals potential signatures of
 protection and pathogenesis in human tuberculosis. *Nature Immunology 2020 21:4*21, 464–476 (2020).
- 711 37. Fonseca, K. L. *et al.* Deficiency in the glycosyltransferase Gcnt1 increases
 712 susceptibility to tuberculosis through a mechanism involving neutrophils. *Mucosal*713 *Immunology* 13, 836–848 (2020).
- 714 38. Nandi, B. & Behar, S. M. Regulation of neutrophils by interferon-γ limits lung
 715 inflammation during tuberculosis infection. *J Exp Med* 208, 2251–2262 (2011).
- 716 39. Dorhoi, A. *et al.* The adaptor molecule CARD9 is essential for tuberculosis control.
 717 *J Exp Med* 207, 777–792 (2010).
- 40. Berry, M. P. R. *et al.* An interferon-inducible neutrophil-driven blood
 transcriptional signature in human tuberculosis. *Nature* 466, 973–977 (2010).
- Tabone, O. *et al.* Blood transcriptomics reveal the evolution and resolution of the
 immune response in tuberculosis. *Journal of Experimental Medicine* 218, (2021).
- 42. Krause, R. *et al.* B cell heterogeneity in human tuberculosis highlights
 compartment-specific phenotype and putative functional roles. *PREPRINT*(Version 1) available at Research Square (2023).
- 43. Stone, R. C. *et al.* Epithelial-Mesenchymal Transition in Tissue Repair and
 Fibrosis. *Cell Tissue Res* 365, 495 (2016).

- Scriba, T. J. *et al.* Sequential inflammatory processes define human progression
 from M. tuberculosis infection to tuberculosis disease. *PLoS Pathog* 13, 1–24
 (2017).
- Thompson, E. G. *et al.* Host blood RNA signatures predict the outcome of
 tuberculosis treatment. *Tuberculosis* 107, 48–58 (2017).
- Tiwari, D. & Martineau, A. R. Inflammation-mediated tissue damage in pulmonary
 tuberculosis and host-directed therapeutic strategies. *Semin Immunol* 65, 101672
 (2023).
- Malherbe, S. T. *et al.* Quantitative 18F-FDG PET-CT scan characteristics correlate
 with tuberculosis treatment response. *EJNMMI Res* 10, 1–15 (2020).
- Kurbatova, E. V. *et al.* Sputum culture conversion as a prognostic marker for endof-treatment outcome in patients with multidrug-resistant tuberculosis: a
 secondary analysis of data from two observational cohort studies. *Lancet Respir Med* 3, 201–209 (2015).
- 49. Wallis, R. S. *et al.* Biomarkers for tuberculosis disease activity, cure, and relapse. *Lancet Infect Dis* 9, 162–172 (2009).
- 50. Assemie, M. A., Alene, M., Petrucka, P., Leshargie, C. T. & Ketema, D. B. Time
 to sputum culture conversion and its associated factors among multidrug-resistant
 tuberculosis patients in Eastern Africa: A systematic review and meta-analysis. *Int J Infect Dis* 98, 230–236 (2020).
- 747 51. Honeyborne, I. *et al.* Profiling persistent tubercule bacilli from patient sputa during
 748 therapy predicts early drug efficacy. *BMC Med* 14, (2016).
- Kempker, R. R., Vashakidze, S., Solomonia, N., Dzidzikashvili, N. & Blumberg,
 H. M. Surgical treatment of drug-resistant tuberculosis. *Lancet Infect Dis* 12, 157–
 166 (2012).
- 53. Hunter, L., Hingley-Wilson, S., Stewart, G. R., Sharpe, S. A. & Salguero, F. J.
 Dynamics of Macrophage, T and B Cell Infiltration Within Pulmonary
 Granulomas Induced by Mycobacterium tuberculosis in Two Non-Human Primate
 Models of Aerosol Infection. *Front Immunol* 12, 776913 (2022).
- 756 54. Canetti, G. *The Tubercle Bacillus in the Pulmonary Lesion of Man:*757 *Histobacteriology and Its Bearing on the Therapy of Pulmonary Tuberculosis.*758 (Springer Publishing Company, 1955).

759	55.	Ewels, P., Magnusson, M., Lundin, S. & Käller, M. MultiQC: Summarize analysis
760		results for multiple tools and samples in a single report. Bioinformatics 32, 3047-
761		3048 (2016).
762	56.	Bolger, A. M., Lohse, M. & Usadel, B. Trimmomatic: A flexible trimmer for
763		Illumina sequence data. Bioinformatics 30, 2114–2120 (2014).
764	57.	Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics
765		25 , (2009).
766	58.	Love, M. I., Huber, W. & Anders, S. Moderated estimation of fold change and
767		dispersion for RNA-seq data with DESeq2. Genome Biol 15, 550 (2014).
768	59.	Hänzelmann, S., Castelo, R. & Guinney, J. GSVA: Gene set variation analysis for
769		microarray and RNA-Seq data. BMC Bioinformatics 14, 1-15 (2013).
770	60.	Langfelder, P. & Horvath, S. WGCNA: An R package for weighted correlation
771		network analysis. BMC Bioinformatics 9, 1-13 (2008).
772	61.	Liberzon, A. et al. Molecular signatures database (MSigDB) 3.0. Bioinformatics
773		27 , 1739–1740 (2011).
774	62.	Yu, G., Wang, L. G., Han, Y. & He, Q. Y. clusterProfiler: an R package for
775		comparing biological themes among gene clusters. OMICS 16, 284–287 (2012).
776	63.	Yaari, G., Bolen, C. R., Thakar, J. & Kleinstein, S. H. Quantitative set analysis for
777		gene expression: A method to quantify gene set differential expression including
778		gene-gene correlations. Nucleic Acids Res 41, 1-11 (2013).
779	64.	Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical
780		and Powerful Approach to Multiple Testing. Journal of the Royal Statistical
781		Society: Series B (Methodological) 57 , 289–300 (1995).
782		




Figure 1. Overall study plan. Overview of the analysis undertaken in the study. Figures associated with each objective are stated.

Granuloma vs Non-lesional tissue Gene expression (13 patients; RNA-seq)






Figure 2. The human TB granuloma signature shows a distinct and heterogeneous transcriptional profile as compared with non-lesional lung tissue. Granuloma samples were collected from each patient included in the SH-TBL cohort: central lesion (C), internal wall (I) and external wall (E) and, altogether, samples from each patient represent the human TB granuloma (G). An additional sample from surrounding non-lesional lung tissue (NL) was also collected from the same patient as control (**Panel a**). 44 samples from 13 patients (7 DS-TB and 6 MDR/XDR-TB) were RNA sequenced to evaluate the human TB lung granuloma transcriptomic changes. A set of 4,630 DGES was identified after comparing the human TB granuloma counts with NL lung tissue expression, using DESeq2 with adjusted p<0.05. **Panel b** heatmap depicts the top 40 DEGs ranked by the adjusted p-value comparing the human TB granuloma versus NL lung tissue expression profiles. The intensity of each colour denotes the standardized ratio between each value and the average expression of each gene across all samples. Red pixels correspond to an increased abundance of mRNA in the indicated sample, whereas blue pixels indicate decreased mRNA levels.

а

RNA-seq of granuloma compartments (44 paired samples from13 patients)





С

Key modules associated to granuloma compartments




Figure 3. The human lung granuloma compartments have different gene expression profiles and are enriched for immune inflammatory response pathways. Panel a show the enrichment score derived from single sample analysis GSEA using the top 40 genes discriminating granuloma from NL lung tissue. Heatmaps showing differences in the top 40 ranked genes from DESeg2 with adjusted p<0.05 by separately comparing the central (C), internal (I) and external (E) compartments with the NL lung tissue gene expression derived (Panel b). The intensity of each colour denotes the standardized ratio between each value and the average expression of each gene across all samples. Red pixels correspond to an increased abundance of mRNA in the indicated sample, whereas blue pixels indicate decreased mRNA levels. Panel c pictures modular transcriptional of the seventeen modules of co-expressed genes derived from WGCNA for our granuloma dataset separated by compartment. Fold enrichment scores derived using QuSAGE are depicted, with red and blue indicating modules over or under expressed compared to the control. Only modules with fold enrichment (FDR) < 0.1 were considered significant.






Figure 4. Granuloma modular transcriptional signature correlates with TB clinical and microbiological characteristics revealing differential responses between patient's group. Modular analysis of granuloma RNA-seq samples from 13 patients. Patients clinically defined accordingly to sputum culture conversion (SCC) and TB disease impact on lung function, measured using the Saint George's Respiratory Questionnaire (SGRQ) symptom score, as surrogates of TB severity and treatment response. Heatmap represent the key granuloma modules significantly associated to individual's' clinical surrogates of TB severity and treatment response (**Panel a**). Fold enrichments were calculated for each WGCNA module using hypergeometric distribution to assess whether the number of genes associated with each clinical status is larger than expected. Fold enrichment scores derived using QuSAGE are depicted, with red and blue indicating modules over or under expressed compared to the control. The colour intensity represents degree of perturbation. Modules with fold enrichment scored FDR p-value < 0.1 are considered significant. **Panel b** and **c** show TB individuals' stratification according to SCC (fast or slow converters) and SGRQ symptom score (low impact if SGRQ > 20), respectively, and the significant association using their corresponding derived WGCNA significant eigengene modules (ME) (p<0.05).





2

Extended data Figure 1. Differential expression analysis of human TB lung granuloma and
separated compartments relative to non-lesional lung tissue. Panel a) Volcano plot depicts
differentially expressed genes (DEGs) between granuloma and non-lesional (NL) lung tissue.
Panel b) Volcano plot depicts DEGs between Central, Internal and External compartments and
the non-lesional (NL) lung tissue. Genes with the adjusted *p*-value ≤0.05 were considered
significantly down-regulated when the log2 fold change was < 0.1 (blue) and up-regulated when
log2fold change > 0.1 (red).

10

12

Supplementary Information

Supplementary Table 1. Demographic and clinical and TB-related patients' characteristics at time of surgery.

Variable	Category	Overall	Male	Female	<i>p</i> -value			
Ν		<i>N</i> = 14	<i>n</i> = 7	<i>n</i> = 7				
Clinical & epidemiological characteristics								
Age [mean (SD)]		34.36 (12.02)	37 (15.56)	31 (7.39)	0.4387 [a]			
BMI [median (range)]		23.55 [19.1-32]	23.4 [21.5-31-7]	23.7 [19.1-32]	0.6841 [b]			
\mathbf{C} and \mathbf{I} and \mathbf{C}	Yes 4 (28.57) 4 (57.14) 0 (0)		0 (0)	0.0699 [c]				
Smoker (%)	No	10 (71.43)	3 (42.86)	7 (100)	U.U099 [C]			
$A \log \log 1 \left(0 \right)$	Yes	5 (35.71)	5 (71.43)	0 (0)	0.0210* [c]			
Alcohol (%)	No	9 (64.29)	2 (28.57)	7 (100)				
Comorbidities (HCV, HBV, Diabetes) (%)	Yes	6 (42.86)	3 (42.86)	3 (42.86)	1 [c]			
HBV, Diabetes) (%)	No	8 (57.14)	4 (57.14)	4 (57.14)				
Characteristics of curre	ent TB episode							
Patient history (%)	Relapse 5 (37.71) 2 (28.57) 3	3 (42.86)	1 [_]					
Fatient history (%)	New patient	9 (64.29)	5 (71.43)	4 (57.14)	1 [c]			
	DS-TB	7 (50)	3 (42.86)	3 (42.86)	1 [c]			
Drug Sensitivity (%)	MDR/XDR-TB	7 (50)	4 (57.14)	4 (57.14)				
Fast (≤2 months) and slow (>2 months) time	Fast converters	8 (57.14)	3 (42.86)	5 (71.43)	0.5921 [c]			
to sputum culture conversion	Slow converters	6 (42.86)	4 (57.14)	2 (28.57)				
Multiple lesions in the	Yes (≥2)	4 (28.57)	2 (28.57)	2 (28.57)	1 [c]			
CXR	No (<2)	10 (71.43)	5 (71.43)	5 (71.43)				
Macroscopic and micro	acroscopic and microbiological characteristics of the TB lesions							
Size of resected lesions (mm) [median (range)]		30 [29-42]	30 [30-35]	30 [29-42]	0.4371 [b]			
Necrosis (%)	Fresh	13 (92.86)	6 (85.71)	7 (100)	1 [0]			
10010315 (70)	Not fresh necrosis	1 (7.14)	1 (14.29)	0 (0)	1 [c]			
Granuloma biopsy	Positive	1 (17.14)	1 (14.29)	0 (0)	1 Г Э			
culture conversion by patient (%)	Negative	13 (92.86)	6 (85.71)	7 (100)	1 [c]			

¹⁵

Statistics: [a] t-test, [b] Mann-Whitney U-test, [c] Fisher's exact test. *Statistically significant differences (fb7and in alcohol use only).

18

20 Supplementary Table 2 - Characteristics of resected lesions from TB patients according to treatment

- 21 response.
- 22

Variable	Category	Overall	Fast Responders	Slow Responders	<i>p</i> -value
Ν		N = 14	<i>n</i> = 8	<i>n</i> = 6	
Size of resected lesion (mm) [median (range)]		30 [29-42]	30 [29-42]	32.5 [30-40]	0.5035 [a]
Neorogia (0/)	Fresh necrosis	13 (92.86)	8 (100)	5 (83.33)	0.4286 [b]
Necrosis (%)	Not fresh necrosis	1 (7.14)	0 (0)	1 (16.67)	
Constantion $(0/)$	Cavitation	11 (78.57)	5 (62.5)	6 (100)	0.2088 [b]
Cavitation (%)	Tuberculoma	3 (21.43)	3 (37.5)	0 (0.00)	
Biopsy culture positivity	7				
Biopsy culture	Positive	1 (7.14)	0 (0.00)	1 (16.67)	0.4286 [b]
conversion by patient (%) 23	Negative	13 (92.86)	8 (100)	5 (83.33)	

Statistics: [a] Mann-Whitney U-test, [b] Fisher's exact test.

C255n parisons refer to patients presenting microbiological conversion at two months or less against those w266 required more than two months to respond to standard anti-TB treatment.

27